- Home
- LQDA vs GNL Comparison
LQDA vs GNL Comparison
Compare LQDA & GNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- GNL
- Stock Information
- Founded
- LQDA 2004
- GNL 2011
- Country
- LQDA United States
- GNL United States
- Employees
- LQDA N/A
- GNL N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- GNL Real Estate Investment Trusts
- Sector
- LQDA Health Care
- GNL Real Estate
- Exchange
- LQDA Nasdaq
- GNL Nasdaq
- Market Cap
- LQDA 1.9B
- GNL 1.7B
- IPO Year
- LQDA 2018
- GNL N/A
- Fundamental
- Price
- LQDA $24.53
- GNL $7.61
- Analyst Decision
- LQDA Strong Buy
- GNL Buy
- Analyst Count
- LQDA 9
- GNL 3
- Target Price
- LQDA $32.67
- GNL $8.67
- AVG Volume (30 Days)
- LQDA 2.2M
- GNL 1.3M
- Earning Date
- LQDA 11-03-2025
- GNL 11-05-2025
- Dividend Yield
- LQDA N/A
- GNL 9.94%
- EPS Growth
- LQDA N/A
- GNL N/A
- EPS
- LQDA N/A
- GNL N/A
- Revenue
- LQDA $19,322,000.00
- GNL $768,986,000.00
- Revenue This Year
- LQDA $424.31
- GNL N/A
- Revenue Next Year
- LQDA $359.32
- GNL N/A
- P/E Ratio
- LQDA N/A
- GNL N/A
- Revenue Growth
- LQDA 30.20
- GNL 24.38
- 52 Week Low
- LQDA $9.71
- GNL $6.51
- 52 Week High
- LQDA $29.94
- GNL $8.35
- Technical
- Relative Strength Index (RSI)
- LQDA 52.65
- GNL 39.44
- Support Level
- LQDA $22.05
- GNL $7.50
- Resistance Level
- LQDA $24.34
- GNL $7.73
- Average True Range (ATR)
- LQDA 1.26
- GNL 0.16
- MACD
- LQDA 0.10
- GNL -0.02
- Stochastic Oscillator
- LQDA 60.51
- GNL 9.80
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.